Develops clinical-stage antiviral therapeutics targeting rhinovirus to prevent and treat viral respiratory infections that trigger COPD and asthma exacerbations. Aims to reduce acute exacerbations, chronic inflammation, hospitalizations and death by addressing the upstream cause rather than downstream management.